Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status

Anemia Clinical Trial

Official title:

Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02835937
• Other study ID #: 15-006487
• Status: Completed
• Phase: N/A
• Start date: September 1, 2016
• Est. completion date: November 10, 2017

Study information

• Verified date: February 2019
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Do ambulatory RBC transfusions improve home functional status?

Description:

Background: Red blood cell (RBC) transfusion is frequently employed in both ambulatory and hospital environments with the aim of improving patient functional status. The efficacy of this 10.5 billion dollar per year practice however has been increasingly called into question. The Investigators propose to directly measure the impact of outpatient RBC transfusions on at-home functional status by recording several physiological parameters and quantifiable physical activity metrics, e.g. daily energy expenditure and daily total step count, using the ActiGraph wGT3X-BT. This device is an accelerometer-based wearable similar in size to a small watch and is worn at the waist. Study participants will wear the device during the course of their daily activities giving the investigators quantifiable insight into activity levels in the home environment.

Methods/Design: This will be a randomized crossover pilot clinical trial with participant study duration of 28 days. The crossover nature allows each patient to serve as his/her own control. Details of the study design are provided in the text. Briefly, patients presenting at Mayo Clinic Scottsdale's Ambulatory Infusion Center (AIC) will be randomized to one of two arms: 1) receive an RBC transfusion as scheduled (transfuse), or 2) abstain from the scheduled transfusion (no-transfuse). After an appropriate washout period, patients will cross from the transfuse arm to the no-transfuse arm or vice-versa. Activity levels will be recorded continuously throughout the study with no need for intervention by the patient. In addition to device data, survey data will be collected via a weekly telephone interview. The primary outcome measures will include both technical performance metrics such as daily energy expenditure as well as practical performance metrics such as changes in step count. A variety of secondary outcome measures include daily sedentary time and PROMIS Global 10 scores.

Discussion: This trial will directly assess the impact of red blood cell transfusion on patient functional status in the location most important - the home. Patient recruitment will begin in August 2016 and is due to be completed in August 2017.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 10, 2017
• Est. primary completion date: November 10, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• At least on prior encounter in the AIC

• Planned RBC transfusion

Exclusion Criteria:

• Refusal to provide informed consent

• Refusal by the health care team

• Acute ischemia (e.g. MI, CVA)

• Hemoglobin < 7.0 g/dL

• Active bleeding

• Symptomatic anemia (hypotension, tachycardia, angina, syncope/pre-syncope believed related to anemia

• Non-ambulatory functional status

• Established or Uncertain Pregnancy Status

Related Conditions & MeSH terms

• Ambulatory Care
• Anemia
• Hematology
• Oncology
• Red Blood Cell Transfusions

Intervention

Other:
• No-Transfuse
Patients will not receive an otherwise-indicated red blood cell transfusion

Locations

Country	Name	City	State
United States	Mayo Clinic in Arizona	Scottsdale	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	Project Honeybee -- The Biodesign Institute at Arizona State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change in Average Daily Physical Activity		Baseline to 7 Days